RS51076B - Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova - Google Patents
Stabilizovani superzasićeni tvrdi rastvori steroidnih lekovaInfo
- Publication number
- RS51076B RS51076B RSP-2009/0508A RSP20090508A RS51076B RS 51076 B RS51076 B RS 51076B RS P20090508 A RSP20090508 A RS P20090508A RS 51076 B RS51076 B RS 51076B
- Authority
- RS
- Serbia
- Prior art keywords
- solid solutions
- supersaturated solid
- steroidal drugs
- stabilised
- stabilised supersaturated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Praškasta kompozicija, naznačena time, da sadrži steroidni molekul; i amorfnu siliku koja poseduje specifičnu površinu od najmanje 250 m2/g; gde je steroidni molekul rastvoren u rastvaraču apsorbovanom na površinu amorfne silike i gde je steroidni molekul prisutan u rastvaraču u superzasićenoj koncentraciji.Prijava sadrži još 12 patentnih zahteva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55133004P | 2004-03-10 | 2004-03-10 | |
EP04075714 | 2004-03-10 | ||
PCT/IB2005/000748 WO2005087199A2 (en) | 2004-03-10 | 2005-03-10 | Stabilised supersaturated solid solutions of steroidal drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
RS51076B true RS51076B (sr) | 2010-10-31 |
Family
ID=34928105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2009/0508A RS51076B (sr) | 2004-03-10 | 2005-03-10 | Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova |
Country Status (33)
Country | Link |
---|---|
US (1) | US8715735B2 (sr) |
EP (2) | EP1765290B1 (sr) |
JP (1) | JP5006185B2 (sr) |
KR (1) | KR101210695B1 (sr) |
CN (1) | CN1984644B (sr) |
AR (1) | AR048500A1 (sr) |
AT (1) | ATE442131T1 (sr) |
AU (1) | AU2005221403B8 (sr) |
BR (1) | BRPI0507342A (sr) |
CA (1) | CA2558582C (sr) |
CR (1) | CR8630A (sr) |
DE (1) | DE602005016551D1 (sr) |
DK (1) | DK1765290T3 (sr) |
EA (1) | EA012746B1 (sr) |
EC (1) | ECSP066902A (sr) |
ES (2) | ES2332229T3 (sr) |
GT (1) | GT200500045A (sr) |
HK (1) | HK1103660A1 (sr) |
HR (1) | HRP20090614T1 (sr) |
IL (1) | IL177894A0 (sr) |
MY (1) | MY142989A (sr) |
NO (1) | NO20064473L (sr) |
NZ (1) | NZ549793A (sr) |
PA (1) | PA8626101A1 (sr) |
PE (1) | PE20060016A1 (sr) |
PL (1) | PL1765290T3 (sr) |
PT (1) | PT1765290E (sr) |
RS (1) | RS51076B (sr) |
SI (1) | SI1765290T1 (sr) |
SV (1) | SV2005002044A (sr) |
TW (1) | TWI345986B (sr) |
UY (1) | UY28803A1 (sr) |
WO (1) | WO2005087199A2 (sr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
CA2612456C (en) * | 2005-06-16 | 2017-06-06 | Warner Chilcott Company, Inc. | Gel compositions for topical administration |
CN101237851B (zh) * | 2005-06-16 | 2013-09-18 | 沃纳奇尔科特有限责任公司 | 用于***给药的***组合物 |
CN101484140B (zh) * | 2006-05-10 | 2012-10-03 | 赢创德固赛有限责任公司 | 辊压热解制备的二氧化硅在药物组合物中的应用 |
BRPI0807581A2 (pt) | 2007-02-23 | 2014-07-01 | Gilead Science Inc | Moduladores de propriedades farmacocinéticas de produtos terapêuticos |
JP5600058B2 (ja) * | 2007-04-11 | 2014-10-01 | ファーマシューティカル プロダクションズ, インコーポレイテッド | メラトニンタブレットならびに調剤及び使用方法 |
KR20100125309A (ko) * | 2008-02-13 | 2010-11-30 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 에스트라디올-함유 약물 전달 시스템 |
CA2718255C (en) * | 2008-03-11 | 2016-08-23 | Aska Pharmaceutical Co., Ltd. | Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
CN104940937A (zh) | 2008-05-02 | 2015-09-30 | 吉里德科学公司 | 固体载体颗粒在改善药物制剂加工性中的应用 |
WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
EP2381946A4 (en) * | 2008-10-10 | 2012-08-08 | Teva Womens Health Inc | METHOD FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN CASE RATED PROSTATE RAY PATIENTS WITH LOW-DOSED CYPROTERONE ACETATE |
CA2752805A1 (en) * | 2009-02-18 | 2010-08-26 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
CN102413813B (zh) * | 2009-03-24 | 2014-11-12 | Adds制药有限责任公司 | 用于口服递送的稳定化的溶解性增强的制剂 |
FR2947178B1 (fr) * | 2009-06-29 | 2012-07-06 | Effik | Composition pharmaceutique a base de progesterone micronisee et ses utilisations |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
CA2992923C (en) | 2014-07-21 | 2021-06-29 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal and sublingual administration of cannabinoids |
AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
CN106109420B (zh) * | 2016-08-11 | 2018-07-06 | 吴启旸 | 依普利酮固体分散体及其制剂 |
AU2018222468B2 (en) * | 2017-02-14 | 2023-05-11 | Dsm Ip Assets B.V. | Water dispersible formulations |
EA201991798A1 (ru) * | 2017-02-14 | 2019-12-30 | ДСМ АйПи АССЕТС Б.В. | Стабильные при хранении составы |
CN110013467B (zh) * | 2018-01-10 | 2021-09-17 | 上海汉都医药科技有限公司 | 一种固体微粒及其制备方法和含其的药物组合物 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA72698B (en) * | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
GB8403359D0 (en) | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
DE3916112A1 (de) * | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
US5183662A (en) | 1990-08-30 | 1993-02-02 | Senju Pharmaceutical Co., Ltd. | Controlled drug release composition |
EP0492007B1 (en) * | 1990-11-29 | 1995-02-08 | F.H. FAULDING & CO. LIMITED | Process for producing liquid loaded powders |
DE4326240A1 (de) * | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
KR20000000016A (ko) | 1999-02-10 | 2000-01-15 | 김일 | 자동차용번호판부착볼트구조 |
ATE254464T1 (de) | 1999-08-31 | 2003-12-15 | Schering Ag | Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
ATE305789T1 (de) | 2000-01-18 | 2005-10-15 | Schering Ag | Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
EA006777B1 (ru) * | 2001-06-22 | 2006-04-28 | Пфайзер Продактс Инк. | Фармацевтические композиции адсорбатов аморфного лекарственного средства |
ITMC20010031U1 (it) | 2001-07-05 | 2003-01-07 | Best Raffaello Srl | Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo |
SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
US7943602B2 (en) | 2002-09-05 | 2011-05-17 | Pantarhei Bioscience B.V. | Pharmaceutical application of 15- or 16-substituted testosterone analogues |
PT1558265E (pt) | 2002-11-05 | 2010-03-22 | Bayer Schering Pharma Ag | Utilização da drospirenona para o tratamento da hipertensão |
DE20217332U1 (de) | 2002-11-11 | 2003-02-27 | Brand Factory Swiss Gmbh, Rotkreuz | Socke |
CA2516096A1 (en) | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
FR2851918B1 (fr) * | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
ES2325591T3 (es) | 2004-03-10 | 2009-09-09 | Bayer Schering Pharma Aktiengesellschaft | Composiciones que comprenden drospirenona dispersada molecularmente. |
-
2005
- 2005-03-09 MY MYPI20050963A patent/MY142989A/en unknown
- 2005-03-10 WO PCT/IB2005/000748 patent/WO2005087199A2/en active Application Filing
- 2005-03-10 UY UY28803A patent/UY28803A1/es not_active Application Discontinuation
- 2005-03-10 CA CA2558582A patent/CA2558582C/en not_active Expired - Fee Related
- 2005-03-10 EP EP05718248A patent/EP1765290B1/en active Active
- 2005-03-10 SI SI200530840T patent/SI1765290T1/sl unknown
- 2005-03-10 CN CN2005800150633A patent/CN1984644B/zh not_active Expired - Fee Related
- 2005-03-10 NZ NZ549793A patent/NZ549793A/en unknown
- 2005-03-10 TW TW094107345A patent/TWI345986B/zh not_active IP Right Cessation
- 2005-03-10 AR ARP050100924A patent/AR048500A1/es not_active Application Discontinuation
- 2005-03-10 RS RSP-2009/0508A patent/RS51076B/sr unknown
- 2005-03-10 PE PE2005000277A patent/PE20060016A1/es not_active Application Discontinuation
- 2005-03-10 JP JP2007502437A patent/JP5006185B2/ja not_active Expired - Fee Related
- 2005-03-10 PA PA20058626101A patent/PA8626101A1/es unknown
- 2005-03-10 AT AT05718248T patent/ATE442131T1/de active
- 2005-03-10 BR BRPI0507342-1A patent/BRPI0507342A/pt not_active IP Right Cessation
- 2005-03-10 EP EP09161378A patent/EP2087883B1/en active Active
- 2005-03-10 DE DE602005016551T patent/DE602005016551D1/de active Active
- 2005-03-10 ES ES05718248T patent/ES2332229T3/es active Active
- 2005-03-10 PL PL05718248T patent/PL1765290T3/pl unknown
- 2005-03-10 GT GT200500045A patent/GT200500045A/es unknown
- 2005-03-10 EA EA200601588A patent/EA012746B1/ru not_active IP Right Cessation
- 2005-03-10 PT PT05718248T patent/PT1765290E/pt unknown
- 2005-03-10 AU AU2005221403A patent/AU2005221403B8/en not_active Ceased
- 2005-03-10 ES ES09161378T patent/ES2390406T3/es active Active
- 2005-03-10 SV SV2005002044A patent/SV2005002044A/es unknown
- 2005-03-10 DK DK05718248T patent/DK1765290T3/da active
- 2005-03-10 US US11/076,022 patent/US8715735B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 IL IL177894A patent/IL177894A0/en unknown
- 2006-09-14 CR CR8630A patent/CR8630A/es unknown
- 2006-10-02 EC EC2006006902A patent/ECSP066902A/es unknown
- 2006-10-02 NO NO20064473A patent/NO20064473L/no not_active Application Discontinuation
- 2006-10-09 KR KR1020067020937A patent/KR101210695B1/ko not_active IP Right Cessation
-
2007
- 2007-11-12 HK HK07112356.6A patent/HK1103660A1/xx not_active IP Right Cessation
-
2009
- 2009-11-16 HR HR20090614T patent/HRP20090614T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51076B (sr) | Stabilizovani superzasićeni tvrdi rastvori steroidnih lekova | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
WO2003087094A3 (en) | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors | |
CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
FR2909284B1 (fr) | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien | |
BR0210519A (pt) | Composições farmacêuticas de adsorvatos de fármaco amorfo | |
HK1140947A1 (en) | Pharmaceuticals compositions of a neuroactive steroid and uses thereof | |
DE602004007257D1 (de) | Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen | |
IS6344A (is) | Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja | |
DK1244401T3 (da) | Medikamentdosering af faseændrende formulering | |
DK1501485T3 (da) | Tablet med höjt indhold af aktivt stof | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
DE60105448D1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
UY29771A1 (es) | Nueva forma cristalina | |
DE60332393D1 (de) | Flüssige pharmazeutische zusammensetzung mit pyridonderivaten | |
ATE401875T1 (de) | Pharmazeutische feste dispersionen von modafinil- verbindungen | |
RS52777B (sr) | Terapijski sistem sa trenutnim otpuštanjem za poboljšanu oralnu apsorpciju 7-[(e)-tert-butiloksiiminometil] kamptotecina | |
CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
ATE267601T1 (de) | Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure | |
ATE491447T1 (de) | Flavonoide und tocotrienole enthaltende zusammensetzungen und deren verwendungen | |
PE20070529A1 (es) | Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion | |
RS51534B (sr) | Novi spoj inihbitora sinusoidne if struje i kalcijumskog inhibitora i farmaceutske smeše koje ga sadrže | |
DE60301261D1 (de) | Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist |